Savak Teymoorian

Savak Teymoorian


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
STSavak Teymoorian
Savak Teymoorian
JKJasmin Kaur
Jasmin Kaur
Purpose: To assess real-world efficacy and safety of standalone travoprost intracameral implant (iDose TR) implantation by a US glaucoma surgeon in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods: This non-randomized, retrospective, unmasked, consecutive case series included all cases of standalone iDose TR implantation from a single US glaucoma surgeon since the product’s approval by the US Food and Drug Administration (FDA) in December 2023. Patients were pseudophakic, had OAG or OHT, and had undergone prior SLT and/or bimatoprost intracameral implant injection (Durysta). Intraocular pressure (IOP), medications, and adverse events were evaluated through 3 months postoperatively. Results: All patients (n=65 eyes) were implanted with iDose TR and experienced no intraoperative complications. In the consistent cohort of eyes with 3-month follow-up data (n=54), mean IOP reduced from 19.6± 3.8 mmHg preoperatively to 13.1± 2.5 mmHg at 3 months (33.2% reduction, p=0.001). The percentage of eyes with IOP ≤ 15 mmHg increased from 11.1% preoperatively to 83.3% at 3 months (p=0.001). Mean number of IOP-reducing medications reduced from 0.28± 0.71 preoperatively to 0.0± 0.0 at 3 months (100% reduction; p=0.006). The percentage of eyes off topical medication increased from 85% preoperatively to 100% at 3 months. One eye was reported to have mild iritis at 1– 2 weeks postoperatively, and was treated with a topical prednisolone acetate taper. No secondary procedures occurred in any eye. Conclusion: Standalone implantation of the travoprost intracameral implant yielded statistically and clinically significant IOP and medication reductions through 3 months in eyes with prior SLT and/or bimatoprost intracameral implant injection with favorable safety. Plain Language Summary: This short-term real-world consecutive case series assesses the efficacy and safety of the novel travoprost intracameral implant (iDose TR) in actual clinical practice. Clinically and statistically significant reductions in intraocular pressure (IOP; 33.2% reduction) and topical medications were achieved, together with favorable safety. After the procedure, there was over a seven-fold increase in the percentage of eyes with IOP ≤ 15 mmHg, and 100% of eyes were free of topical medications (versus 85.2% preoperatively). This publication is the first real-world study in the literature to-date on this novel technology.

7 April 2026 in Life
Verified
Journal Article
Open access
PDF file
STSavak Teymoorian
Savak Teymoorian
JKJasmin Kaur
Jasmin Kaur
DHDana Hornbeak
Dana Hornbeak
EBErik Barr
Erik Barr
This retrospective study evaluated real-world outcomes of standalone iDose TR intracameral travoprost implant administration. Sixty-five consecutive standalone iDose TR implantations performed by a single surgeon were analyzed. Patients were pseudophakic, had a diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT), and had a history of a prior non-filtering glaucoma procedure (e.g., selective laser trabeculoplasty [SLT] or bimatoprost intracameral implant) performed beyond the preceding 6 months. Intraocular pressure (IOP) and medications were measured for 12 months postoperatively. Subgroup analysis was stratified by history of SLT treatment and glaucoma severity. If target IOP was not attained, secondary minimally invasive glaucoma surgery was performed instead of reinitiating or adding medication, according to the surgeon’s standard practice. The analysis was by intention to treat. At 12 months, mean IOP reduced significantly to 14.0 ± 2.9 mmHg from a baseline of 20.0 ± 4.0 mmHg (−28%, p < 0.001). Eyes with IOPs ≤ 18, ≤15, and ≤12 mmHg increased significantly vs. baseline (36.9% to 92.3%, 10.8% to 73.8%, and 3.1% to 35.4%, respectively; all p < 0.001), and 89.2% of the eyes were medication-free vs. 87.7% preoperatively. Mean 12-month IOP reduction showed nonsignificant differences between eyes with or without prior SLT (−26% and −31%, respectively; p = 0.907) and among mild/OHT, moderate, or severe glaucoma eyes (−28%, −23%, and −34%, respectively; p = 0.085). Postoperatively, one case each of transient corneal edema and retinal edema were observed, which self-resolved without sequelae. Thus, standalone travoprost implant administration significantly reduced IOP over 12 months in OAG and OHT, while maintaining a low medication burden. Similar IOP reductions were observed regardless of prior SLT treatment and glaucoma severity.